EP3260117

AMGEN
Application Number
EP17185704A
Filing Date
Sep 10, 2004
Status
Revoked
Aug 6, 2024
Grant Date
Nov 27, 2019
External Links
Slate, Register, Google Patents
Similar Patents facing opposition

Biblio Summary

The patent EP3260117B8 was granted on Nov 27, 2019 by Amgen . The latest application status of the patent is - Revoked.

AI Generated Summary New

Patent Oppositions filed by Competitors

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

PUREN PHARMAMay 25, 2021INTERVENTION ADMISSIBLE
ARISTO PHARMAApr 14, 2021INTERVENTION ADMISSIBLE
TAD PHARMAMar 8, 2021INTERVENTION ADMISSIBLE
BETAPHARM ARZNEIMITTELNov 24, 2020INTERVENTION ADMISSIBLE
AECHTERJan 17, 2020ADMISSIBLE
BIOGARANJan 17, 2020ADMISSIBLE
HGFJan 17, 2020ADMISSIBLE
ACCORD HEALTHCAREJan 17, 2020WITHDRAWN
GLENMARK PHARMACEUTICALS EUROPEJan 16, 2020ADMISSIBLE
TEVA PHARMACEUTICAL INDUSTRIESJan 14, 2020WITHDRAWN

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents